The IL3 knockout PaTu 8988t polyclonal cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the PaTu 8988t pancreatic ductal adenocarcinoma cell line. These polyclonal cells harbor targeted disruption of the IL3 gene, providing a heterogeneous loss-of-function model that avoids clonal selection bias and is well-suited for functional assays requiring a representative population of edited cells.
The parental PaTu 8988t line is a widely used model of human pancreatic cancer, originally established from a lymph node metastasis. Retaining key tumorigenic features, these adherent epithelial cells are valuable for studying invasion, metastasis, and tumor?Cmicroenvironment interactions. Their metastatic derivation makes them particularly relevant for investigating secreted factors, such as cytokines, that may influence immune cell behavior within the pancreatic tumor milieu.
IL-3 encodes a cytokine that primarily regulates hematopoietic cell proliferation and differentiation, yet its emerging role in solid tumors has garnered increasing attention. The IL-3 protein binds to a heterodimeric receptor consisting of IL3RA (CD123) and CSF2RB (CD131), activating JAK2 and the downstream transcription factor STAT5. This activation promotes transcription of target genes like BCL-2 family members, cyclin D1, and MYC, which drive cell survival and proliferation. Concurrently, IL-3 receptor engagement stimulates the RAS?CRAF?CMEK?CERK (MAPK) and PI3K?CAKT?CmTOR pathways, amplifying mitogenic signals. Upstream regulators include NF-??B, AP-1, and inflammatory cytokines (IL-1, TNF-??), while SOCS family proteins provide negative feedback. In non-hematopoietic contexts, IL-3 signaling may modulate tumor cell growth and microenvironment dynamics.
In PaTu 8988t pancreatic cancer cells, disruption of IL-3 allows researchers to dissect tumor-intrinsic roles of this cytokine within the pancreatic tumor microenvironment. This polyclonal knockout model permits the investigation of how IL-3 loss affects cancer cell proliferation, apoptosis, and paracrine interactions with stromal and immune cells. It is a powerful tool for exploring the IL-3/IL3RA axis in pancreatic cancer biology, evaluating therapeutic targets, and understanding mechanisms of immune evasion and therapy resistance in a disease-relevant context.
Typical applications include RT-qPCR and western blotting for expression validation, flow cytometry for IL3RA, cell proliferation (MTS) and apoptosis (annexin V) assays, and phospho-STAT5 analysis to monitor signaling output. The polyclonal nature supports functional genomics screens and RNA-seq transcriptome profiling without clonal artifacts. For further information or ordering, please contact Ascent Research.
